InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) has developed a pioneering, high-yield biosynthesis process that enables the manufacture of all 90+ naturally occurring cannabinoids. This groundbreaking development could have an enormous impact in forwarding the efforts of other companies within the cannabis sector, including GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Axim Biotechnologies, Inc. (OTCQB: AXIM) and 22nd Century Group, Inc. (NYSE: XXII).